TICKERNERD
Menu
PAVMPAVMHealthcare · Medical Devices

PAVM Stock Forecast: PAVmed, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$5.20
+9.70% on the day

The 2 Wall Street analysts covering PAVmed, Inc. hold a median 12-month price target of $36 — +592.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$37.2M
Ticker Nerd rank
15 / 100
Median analyst target
$36
Analysts covering
2
Total return, dividends reinvested
1W
+9.7%
1M
−8.3%
YTD
−21.6%
1Y
−62.0%
From 52W high
−68.8%
From 52W low
+23.5%
$4
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PAVM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PAVmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Size
85
Volatility
33
Revisions
33
Quality
29
Growth
20
Value
10
Momentum
5
Issuance
4

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PAVM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAVM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26PAVMHigh $56Median $36Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $16Median $36High $56

The green dot is the last close — the median target sits +592.3% from it.

Recent analyst actionsNewest first

Of the 16 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
8 June 2026Ascendiant CapitalMaintainsBuy$65 → $56
9 Apr 2026Ascendiant CapitalMaintainsBuy—
10 Dec 2025Ascendiant CapitalMaintainsBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
9 Dec 2024Ascendiant CapitalMaintainsBuy—
10 Sept 2024Ascendiant CapitalMaintainsBuy$22 → $21
18 Aug 2023Cantor FitzgeraldReiteratesNeutral$1.40
20 Jan 2023Cantor FitzgeraldDowngradeNeutral$4.00 → $1.50
18 Jan 2023Lake StreetMaintainsBuy$5.00 → $1.50
17 Aug 2022Lake StreetMaintainsBuy$7.00 → $5.00
30 Mar 2021Cantor FitzgeraldInitiatesOverweight—
5 Nov 2020Ascendiant CapitalInitiatesBuy—
13 Oct 2020Lake StreetInitiatesBuy—
28 June 2018Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PAVM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PAVM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

PAVmed, Inc. (PAVM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
438.0×

Cheaper than 2% of US stocks

Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
175.0%

Higher than 96% of US stocks

Earnings growth (YoY)
175.0%

Higher than 89% of US stocks

Gross margin
−340.9%

Higher than 1% of US stocks

Operating margin
−36522.7%

Higher than 1% of US stocks

Net margin
−207.0%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−67.2%

Higher than 18% of US stocks

Return on assets
−31.0%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PAVM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PAVMPAVmed, Inc.$37.2M
15
SNWVSANUWAVE Health, Inc.$40.7M
50
NSYSNortech Systems, Inc.$33.7M
89
ELUTElutia, Inc.$41.6M
27
ARAYAccuray, Inc.$33.0M
35
QTIQT Imaging Holdings, Inc.$42.2M
25
XTNTXtant Medical Holdings, Inc.$42.7M
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PAVmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PAVM news & analysis

PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

PAVmed Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the discussion. The transcript covers the company's Q2 2026 results and management commentary from the call.

Why it matters — PAVmed watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's own commentary on its operations.

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PRNewsWire · 14 Aug 2026positive

PAVmed provided a business update and reported financial results for the second quarter ended June 30, 2026. The update noted that Veris Health accelerated commercial engagement with OSU-The James, its implantable physiological monitor achieved development milestones toward an upcoming FDA submission, and Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard. A conference call and webcast were held August 14, 2026.

Why it matters — PAVmed watchers would care because these milestones mark tangible progress for its subsidiaries, including Veris Health advancing its monitor toward an FDA submission and Lucid Diagnostics gaining its first coverage policy for EsoGuard.

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

PRNewsWire · 13 Aug 2026positive

Lucid Diagnostics, a subsidiary of PAVmed, reported second quarter 2026 financial results with $1.5 million in revenue, processed 2,770 EsoGuard tests, and secured its first laboratory benefit manager coverage policy for EsoGuard.

Why it matters — As a wholly owned subsidiary of PAVmed, Lucid's revenue growth and insurance coverage milestone directly impact PAVmed's consolidated financial performance and the valuation of its key asset.

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

PRNewsWire · 5 Aug 2026positive

Lucid Diagnostics, a subsidiary of PAVmed, announced that Concert issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer, recognizing EsoGuard as the only esophageal precancer test meeting its coverage criteria. The policy can be adopted by Concert's client health plans.

Why it matters — A positive commercial coverage policy from Concert could expand access to Lucid's EsoGuard test across multiple health plans, which is significant for PAVmed given Lucid is its subsidiary.

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PRNewsWire · 4 Aug 2026neutral

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., announced that its management will participate in two upcoming investor conferences: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026 (virtual 1x1 meetings), and the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026 (fireside chat in Boston, MA). The Canaccord fireside chat will be webcast live, with a replay available for 30 days on Lucid's website.

Why it matters — This signals that PAVmed's subsidiary Lucid Diagnostics will be engaging with investors at notable industry conferences, offering visibility into the company amid a proposed transaction between PAVmed and Lucid.

FAQ

Frequently asked questions about PAVM stock

What is the PAVM stock price forecast for 2026-2027?

The 2 Wall Street analysts covering PAVmed, Inc. have a median 12-month price target of $36, with estimates ranging from $16 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAVM stock a buy right now?

Of the 2 analysts covering PAVmed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PAVmed, Inc. 15 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAVM?

As at 15 Aug 2026, PAVmed, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will PAVM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +592.3% from the last close, and Ticker Nerd's factor model ranks PAVmed, Inc. 15 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAVM stock forecast for 2030?

No analyst covering PAVmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $56 over the next 12 months.

How has PAVM stock performed over the past year?

PAVmed, Inc. returned -62.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PAVmed, Inc. do?

PAVmed Inc. is a diversified commercial-stage medical technology company focused on developing and commercializing innovative products in the medical device, diagnostics, and digital health sectors.

What is the latest news on PAVM?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript". PAVmed Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the discussion. The transcript covers the company's Q2 2026 results and management commentary from the call.

Company

About PAVmed, Inc.

PAVmed Inc. is a diversified commercial-stage medical technology company focused on developing and commercializing innovative products in the medical device, diagnostics, and digital health sectors. Its portfolio includes specialized tools designed to enhance patient care and clinical outcomes. Through its subsidiary Lucid Diagnostics Inc., PAVmed Inc. markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which enable the early detection of esophageal precancer to help prevent esophageal cancer. Veris Health Inc., another key subsidiary, specializes in digital health solutions for personalized cancer care, featuring implantable biologic sensors for remote patient monitoring, wireless communication, and a suite of connected external devices, alongside an implantable physiological monitor that integrates with the Veris Cancer Care Platform. PAVmed Inc. supports healthcare providers, clinicians, and patients by delivering technologies that address critical needs in oncology and beyond, operating a shared-services model to drive efficiency across its commercial activities.

CEO Dr. Lishan Aklog M.D. · 41 employees · United States · https://www.pavmed.com